SCHEMBL24260613

SCHEMBL24260613

CNc1ccccc1OC(=O)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.47
KDM4E B2RXH2 3/20 0.44
POLB P06746 2/20 0.44
ATM Q13315 1/20 0.44
ADRB2 P07550 1/20 0.44
ADRA2A P08913 1/20 0.44
DRD2 P14416 1/20 0.44
ADRA2C P18825 1/20 0.44
DRD1 P21728 1/20 0.44
ADRA1A P35348 1/20 0.44
DRD3 P35462 1/20 0.44
ALDH1A1 P00352 2/20 0.44
ACHE P22303 1/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 2/20 0.40
MDM4 O15151 1/20 0.40
TP53 P04637 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24260341 0.84 ELANE (0.46) ELANEKDM4EPOLBADRB2ADRA2A
SCHEMBL21771958 0.83 MDM4 (0.57) ELANEKDM4EPOLBALDH1A1KMT2A
SCHEMBL15547599 0.82 ALOX15 (0.55) ELANEKDM4EADRB2ADRA2ADRD2
Bromide SCHEMBL16050020 0.81 ALOX15 (0.53) ELANEKDM4EADRB2ADRA2ADRD2
SCHEMBL31482993 0.79 PTGS2 (0.53) KDM4EPOLBATMALDH1A1ACHE
SCHEMBL6971901 0.79 KDM4E (0.48) KDM4EPOLBATMALDH1A1ACHE
SCHEMBL10607461 0.79 PTGS2 (0.53) KDM4EPOLBATMALDH1A1ACHE
SCHEMBL24260209 0.79 ALDH1A1 (0.43) ELANEKDM4EPOLBALDH1A1KMT2A
SCHEMBL24260224 0.79 ELANE (0.45) ELANEADRB2ADRA2ADRD2ADRA2C
SCHEMBL24260332 0.79 HSD17B10 (0.46) ELANEKDM4EPOLBATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820727-B1 Capsaicinoid prodrug compounds and their use in treating medical conditions CENTREXION THERAPEUTICS CORPORATION (US) 2023-11-21 US disclosed
US-11820727-B1 Capsaicinoid prodrug compounds and their use in treating medical conditions CENTREXION THERAPEUTICS CORPORATION (US) 2023-11-21 US disclosed
US-11254659-B1 Capsaicinoid prodrug compounds and their use in treating medical conditions CENTREXION THERAPEUTICS CORPORATION (US) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820727-B1 Capsaicinoid prodrug compounds and their use in treating medical conditions TRPV1, TRPV2, TRPV3 ELANE 2199/4885KDM4E 3063/4885POLB 4823/4885
US-11254659-B1 Capsaicinoid prodrug compounds and their use in treating medical conditions TRPV1, TRPA1, TRPV2 ELANE 3143/4885KDM4E 3279/4885POLB 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.